Masimo Corp (NASDAQ:MASI), a maker of patient monitoring devices and wearable tech, saw its stock surge higher in Friday's early deals as it was handed a significant win in its patent dispute with ...

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

Masimo Corporation shares fell after announcing a "diworsification" move for Sound United, causing concerns about the company's core expertise. Despite a recovery in share price, the company's seco...

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.

Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...

Masimo Corporation (NASDAQ:MASI ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Eli Kammerman - VP, Business Development & IR Joseph Kiani - Founder, CEO & Chairma...

Masimo (MASI) came out with quarterly earnings of $0.62 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $1.35 per share a year ago.